Comparative Pharmacology
Head-to-head clinical analysis: MYTELASE versus NEOSTIGMINE METHYLSULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTELASE versus NEOSTIGMINE METHYLSULFATE.
MYTELASE vs NEOSTIGMINE METHYLSULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
Inhibits acetylcholinesterase at the neuromuscular junction, increasing acetylcholine availability and enhancing cholinergic transmission.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
0.5-2.5 mg intravenously or intramuscularly every 2-4 hours as needed for reversal of neuromuscular blockade or treatment of myasthenia gravis; for reversal of non-depolarizing neuromuscular blockade, 0.03-0.07 mg/kg intravenously with anticholinergic.
None Documented
None Documented
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Terminal elimination half-life is approximately 0.7 to 1.2 hours (mean 0.8 h) in healthy adults. In renal impairment, half-life may be prolonged up to 3-4 hours, requiring dose adjustment.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Renal excretion of unchanged drug accounts for approximately 50% of elimination; the remainder is metabolized by microsomal enzymes and excreted in urine as metabolites. Biliary/fecal elimination is minimal (<5%).
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor